Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (101-110 of 194) with videos related to

Pageof 20
Sort By:
Deutsches Arzteblatt International|March 18, 2022
Oral Drugs Against COVID-19Gerd Mikus, Kathrin I Foerster, Theresa Terstegen, et al.
Therapeutic Drug Monitoring|December 31, 2010
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoringArwa Hassan, Jürgen Burhenne, Klaus-Dieter Riedel, et al.
European Journal of Clinical Pharmacology|September 13, 2012
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activityInes Fuchs, Verena Hafner-Blumenstiel, Christoph Markert, et al.
Journal of Clinical Pharmacology|February 5, 2015
Pharmacokinetic interaction of intravenous fentanyl with ketoconazoleVictoria C Ziesenitz, Sonja K König, Nina S Mahlke, et al.
European Journal of Clinical Pharmacology|July 26, 2006
Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational ageJens Rengelshausen, Bernd Beedgen, Konstantina Tsamouranis, et al.
British Journal of Clinical Pharmacology|December 17, 2009
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeIna Scholz, Heike Oberwittler, Klaus-Dieter Riedel, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 2, 2021
Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, et al.
European Journal of Clinical Pharmacology|March 3, 2022
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humansAnnika Elbe, Kathrin Isabelle Foerster, Antje Blank, et al.
Basic & Clinical Pharmacology & Toxicology|July 11, 2018
Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditionsMarcus J P Geist, Gerlinde Egerer, Gerd Mikus, et al.
British Journal of Clinical Pharmacology|June 6, 2002
Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor ELMeret Martin-Facklam, Jürgen Burhenne, Reinhard Ding, et al.
Pageof 20

Showing results (101-110 of 194) with videos related to

Sort By:
Pageof 20
Deutsches Arzteblatt International|March 18, 2022
Oral Drugs Against COVID-19Gerd Mikus, Kathrin I Foerster, Theresa Terstegen, et al.
Therapeutic Drug Monitoring|December 31, 2010
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoringArwa Hassan, Jürgen Burhenne, Klaus-Dieter Riedel, et al.
European Journal of Clinical Pharmacology|September 13, 2012
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activityInes Fuchs, Verena Hafner-Blumenstiel, Christoph Markert, et al.
Journal of Clinical Pharmacology|February 5, 2015
Pharmacokinetic interaction of intravenous fentanyl with ketoconazoleVictoria C Ziesenitz, Sonja K König, Nina S Mahlke, et al.
European Journal of Clinical Pharmacology|July 26, 2006
Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational ageJens Rengelshausen, Bernd Beedgen, Konstantina Tsamouranis, et al.
British Journal of Clinical Pharmacology|December 17, 2009
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotypeIna Scholz, Heike Oberwittler, Klaus-Dieter Riedel, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 2, 2021
Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, et al.
European Journal of Clinical Pharmacology|March 3, 2022
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humansAnnika Elbe, Kathrin Isabelle Foerster, Antje Blank, et al.
Basic & Clinical Pharmacology & Toxicology|July 11, 2018
Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditionsMarcus J P Geist, Gerlinde Egerer, Gerd Mikus, et al.
British Journal of Clinical Pharmacology|June 6, 2002
Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor ELMeret Martin-Facklam, Jürgen Burhenne, Reinhard Ding, et al.
Pageof 20